Morphic Therapeutic
OverviewSuggest Edit
Morphic Therapeutic operates as a biotechnology company. The company develops oral integrin drugs. It is advancing preclinical programs in autoimmunity, fibrosis, vascular disorders, and immuno-oncology.
| Type | Public | |
| Founded | 2015 | |
| HQ | Waltham, MA, US | Map |
| Website | morphictx.com | |
| Overall Culture | A+ | More |
Recent NewsAll News
- Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
- Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors
- Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
- Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
Morphic Therapeutic Office Locations
Morphic Therapeutic has an office in Waltham
Waltham, MA, US (HQ)
35 Gatehouse Dr
Morphic Therapeutic Financials and Metrics
Morphic Therapeutic Revenue
Morphic Therapeutic's revenue was reported to be $3.36 m in FY, 2019
| USD | |
|---|---|
Revenue (Q2, 2020) | 7.7m |
Net income (Q2, 2020) | (15.9m) |
EBIT (Q2, 2020) | (16.4m) |
Market capitalization (11-Jan-2021) | 926.6m |
Closing stock price (11-Jan-2021) | 29.8 |
Cash (30-Jun-2020) | 133.1m |
Morphic Therapeutic's current market capitalization is $926.6 m.
Annual
Annual
Annual
| USD | FY, 2017 |
|---|---|
Financial Leverage | 1.2 x |
Morphic Therapeutic Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Morphic Security Corporation |
Morphic Therapeutic Cybersecurity Score
Morphic Therapeutic Online and Social Media Presence
329 Twitter followers
Morphic Therapeutic has 329 Twitter Followers. The number of followers has increased 1.4% month over month and increased 2.7% quarter over quarter
Morphic Therapeutic's Trends
Twitter Engagement Stats for @MorphicTx
71
Tweets
36
Following
329
Followers
2
Tweets last 30 days
11
Avg. likes per Tweet
100%
Tweets with engagement
Morphic Therapeutic Company Culture
Overall Culture
A+
89/100
CEO Rating
A+
100/100
Compensation
A+
95/100
Morphic Therapeutic News and Updates
December 30, 2020
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D., president and chief executive officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conf…
December 04, 2020
Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors
WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W. Edwards, to its Board of Directors. Dr. Edwards is a veteran leader in the drug development industry, r…
November 17, 2020
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that members of the Morphic management are scheduled to…
September 23, 2020
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety and pharmacokinetics of MORF-057 as well as α4β7 receptor occupancy as a clinically relevant biomar…
September 21, 2020
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced two presentations at the Jefferies Next Generation IBD…
June 29, 2020
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020
Receptor occupancy, potency and selectivity data further build MORF-057 preclinical profile as an oral small molecule treatment candidate for IBD
Morphic Therapeutic Blogs
September 03, 2020
Morphic Announces Participation in Upcoming Investor Conferences
Morphic Announces Participation in Upcoming Investor Conferences
Content Import
Thu, 09/03/2020 - 16:30
Morphic Announces Participation in Upcoming Investor Conferences
September 3, 2020 at 4:30 PM EDT
This release is a backfill from a News Wire
…
June 18, 2020
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief
April 07, 2020
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
WALTHAM, Mass. , April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial
March 17, 2020
Morphic Announces Appointment of Peter G. Linde, M.D., as Chief Medical Officer
WALTHAM, Mass. , March 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G.
February 28, 2020
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
Content Import
Fri, 02/28/2020 - 08:01
Morphic Therapeutic to Present at the 40th Annual Cowen Health Care Conference
February 28, 2020 at 8:00 AM EST
This release is a backfill fro…
February 27, 2020
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
Content Import
Thu, 02/27/2020 - 16:06
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
February 27, 2020 at 4:05 PM EST
This release is a ba…
Morphic Therapeutic Frequently Asked Questions
When was Morphic Therapeutic founded?
Morphic Therapeutic was founded in 2015.
How many employees does Morphic Therapeutic have?
Morphic Therapeutic has 76 employees.
What is Morphic Therapeutic revenue?
Latest Morphic Therapeutic annual revenue is $3.4 m.
What is Morphic Therapeutic revenue per employee?
Latest Morphic Therapeutic revenue per employee is $44.2 k.
Who are Morphic Therapeutic competitors?
Competitors of Morphic Therapeutic include MOMA Therapeutics, Zealand Pharma and Twist Bioscience.
Where is Morphic Therapeutic headquarters?
Morphic Therapeutic headquarters is located at 35 Gatehouse Dr, Waltham.
Where are Morphic Therapeutic offices?
Morphic Therapeutic has an office in Waltham.
How many offices does Morphic Therapeutic have?
Morphic Therapeutic has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies